Paclitaxel Serum Concentrations Linked to Severity of Neuropathy in Breast Cancer Patients

January 13, 2018
N. Lynn Henry, MD, PhD

This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses a 60-patient study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

Henry was one of the coauthors of the study (abstract P6-11-03), which was presented during a poster session at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Related Content:

Breast Cancer
FDA Issues Response Letter for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer
Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures
Black Women With Node-Negative Breast Cancer More Likely to Have High-Risk Recurrence Scores Than Non-Hispanic White Women